# ANXA2P2 and PA2G4P4 Pseudogenes Are Associated with the Response to Ionizing Radiation and Could Be Used as Potential Biomarkers: In Silico Study

## TL;DR

This study identifies two pseudogenes, ANXA2P2 and PA2G4P4, as potential biomarkers for predicting cancer aggressiveness and response to radiation therapy in head and neck cancer.

## Contribution

The study reveals the clinical relevance of ANXA2P2 and PA2G4P4 pseudogenes in head and neck squamous cell carcinoma prognosis and radiotherapy response.

## Key findings

- ANXA2P2 and PA2G4P4 are significantly upregulated in HNSCC and linked to adverse clinicopathological features.
- Low expression of both pseudogenes correlates with improved survival and better radiotherapy response.
- Pseudogene expression influences immune profiles and oncogenic pathways in HNSCC.

## Abstract

Background: Head and neck squamous cell carcinoma remains a highly aggressive malignancy with limited predictive biomarkers for prognosis and radiotherapy response. Increasing evidence indicates that pseudogenes are functionally active regulators of cancer biology, yet their clinical relevance in HNSCC is poorly defined. Methods: Using transcriptomic and clinical data from The Cancer Genome Atlas, we analyzed the expression and clinical significance of two pseudogenes, ANXA2P2 and PA2G4P4, in HNSCC. Associations with clinicopathological features, HPV status, tumor subtypes, survival, genomic instability, radiotherapy response, and immune landscape were assessed using bioinformatic tools. Results: Both pseudogenes were significantly upregulated in HNSCC compared to normal tissues. Higher expression levels correlated with adverse clinicopathological features, increased tumor proliferation and wound-healing capacity, and unfavorable TCGA molecular subtypes. High ANXA2P2 and PA2G4P4 expression was associated with reduced overall survival, while their combined low-expression signature identified patients with significantly improved overall and disease-free survival. Notably, lower expression of both pseudogenes was observed in patients responding to radiotherapy, whereas higher expression was linked to genomic instability parameters and enrichment of oncogenic pathways, including MYC, PI3K/AKT/mTOR, cell cycle regulation, and DNA repair. ANXA2P2 expression differed significantly by HPV status, showing reduced levels in HPV-positive tumors. Furthermore, pseudogene expression stratified distinct immune profiles, including immune subtypes, stromal and immune scores, and specific immune cell populations. Conclusions:
ANXA2P2 and PA2G4P4 are clinically relevant pseudogenes associated with tumor aggressiveness, immune modulation, and radiotherapy response in HNSCC. These findings support their potential utility as prognostic and predictive biomarkers and provide a rationale for further functional validation in experimental models.